Selinexor receives FDA approval for relapsed/refractory diffuse large B-cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Selinexor (Xpovio) was granted accelerated approval from FDA for adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

Xpovio is sponsored by Karyopharm Therapeutics.

Approval was based on SADAL (KCP-330-009; NCT02227251), a multicenter, single-arm, open-label trial in patients with DLBCL after two to five systemic regimens. Patients received selinexor 60 mg orally on days one and three of each week.

Efficacy was based on overall response rate and response duration, as assessed by an independent review committee using Lugano 2014 criteria. In 134 patients, the ORR was 29% (95% CI: 22, 38), with complete response in 13%. Of the 39 patients who achieved a partial or complete response, 38% had response durations of at least 6 months and 15% had response durations of at least 12 months.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login